No cause for panic, but an incentive to improve clinical practice
The use of selective serotonin reuptake inhibitors (SSRIs) in depressed children and adolescents has received consider-able attention in the past year; this attention has included concerns about increased suicide risk, revised evidence about effectiveness, growing prescription numbers, and revelations of drug companies withholding data.1 The discovery of unforeseen risks in other drugs such as cyclooxygenase-2 inhibitors has intensified the climate of uncertainty and mistrust about drug treatment. Some argue that to diagnose major depression in children is to medicalise the unhappiness caused by affluence, permissiveness, a decaying family and society.2 By contrast, medical practitioners and governments have been told during the last quarter century that depression is a serious illness that can lead to suicide, poor physical health, and personal, professional and social difficulties. Thus, the Australian community has invested considerable resources in trying to tackle this scourge (eg, The National Depression Initiative3). If experts disagree, it is little wonder that the public and clinicians are confused, yet severely depressed teenagers continue to come to doctors for management.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-1345.
- 2. Timimi S. Rethinking childhood depression. BMJ 2004; 329: 1394-1396.
- 3. Australian Government Department of Health and Aged Care. National action plan for depression. Canberra: Mental Health and Special Programs Branch, 2000.
- 4. Brent DA. Antidepressants and pediatric depression — the risk of doing nothing. N Engl J Med 2004; 351: 1598-1601.
- 5. Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related death and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184: 41-47.
- 6. Gould MS, Greenberg T, Velting DM, Shaffer D. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Psychiatry 2003; 42: 386-405.
- 7. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978-982.
- 8. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm? BMJ 2004; 329: 34-38.
- 9. Isacsson G, Holmgren P, Ahlner J. Do SSRIs induce suicide? A controlled study of Swedish suicides 1992–2000. Eur Neuropsychopharmacol 2004; 14 Suppl 2: 145.
- 10. Moskos M, Olson L, Frazier S, et al. Utah adolescent suicide psychological autopsy study. Suicide Life Threat Behav. In press.
- 11. Donovan S, Clayton A, Beeharry M, et al. Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 2000; 177: 551-556.
- 12. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385-388.
- 13. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338-343.
- 14. Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. In: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Joint Meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee; September 13, 2004: 152-200. Available at: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4065T1.pdf and http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1.htm (accessed Jan 2005).
- 15. Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 725-736.
- 16. Compton SN, March JS, Brent D, et al. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. J Am Acad Child Adolesc Psychiatry 2004; 43: 930-959.
- 17. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA 2004; 292: 807-820.
Professor Rey was a member of the advisory committee for Strattera (Eli Lilly) and Concerta (Janssen-Cilag) and was funded by Eli Lilly to attend an international conference. No agency or other source has funded or influenced the design or content of this article. Dr Dudley has often attended dinners sponsored by Pfizer, and received gifts from various drug companies (bags, CDs, pens etc). This has not influenced the content of this article.